Curaleaf (CURLF) PT Raised to $26.50 at Cantor Fitzgerald Following Q4 Results

March 10, 2021 10:18 AM EST
Get Alerts CURLF Hot Sheet
Price: $13.26 +3.84%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 24 | New: 32
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Pablo Zuanic raised the price target on Curaleaf (OTC: CURLF) to $26.50 (from $23.50) while maintaining an Overweight rating.

The analyst commented, "Curaleaf reported 4Q20 results yesterday after the close, issued guidance, and discussed its European acquisition. Sales guidance for 2021 is in line with our estimates/consensus, and so is the EBITDA margin outlook. Macro issues and COVID explain a slight sales miss in 4Q20, and 1Q21 sales guidance being set below estimates. But to us, the two main themes from Tuesday’s print/call, were the a) increasing evidence of the company leveraging its national scale and capabilities to expand market leadership and profitability in the US market, and b) a $285Mn acquisition in Europe that signals the company’s global ambitions. Canadian LPs without CPG backing trade at 6-10x CY22 on our sales estimates, so we now value Curaleaf at 10x on our proforma CY22 sales estimate ($1.9Bn US and $100Mn EMMAC), which yields a price target of $26.50. We think that the company’s track record and goodwill built over the past four years (from a C$300Mn market cap in 2017 to C$12.5Bn now) should encourage investors to take the company’s global ambitions seriously."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Cantor Fitzgerald, Definitive Agreement